Dyne Therapeutics, Inc. · NASDAQ:DYN

Rhodes Jason P sold 106,723 Dyne Therapeutics, Inc. shares (Form 4)

Traded May 4 to May 6, 2026 · Filed May 6, 2026

From May 4 to May 6, 2026, Rhodes Jason P (Director) sold 106,723 Dyne Therapeutics, Inc. shares at an average US$18.14 for US$1.94M under a trading plan, leaving 1,136,810 shares. Filed May 6, 2026 (Form 4).

Sold
106,723 shares
Price
US$18.14 average (US$18.00 to US$18.18)
Value
US$1.94M
Holding after
1,136,810 shares (held indirectly)
Trading plan
Yes (Made under a plan set in advance)
Role
Director

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
May 4, 2026Common StockSale3,136US$18.001,574,270Indirect
May 4, 2026Common StockSale6,241US$18.004,933,196Indirect
May 4, 2026Common StockSale61US$18.008,450Indirect
May 4, 2026Common StockSale2,466US$18.001,156,457Indirect
May 5, 2026Common StockSale3,056US$18.031,571,214Indirect
May 5, 2026Common StockSale6,081US$18.034,927,115Indirect
May 5, 2026Common StockSale60US$18.038,390Indirect
May 5, 2026Common StockSale2,403US$18.031,154,054Indirect
May 6, 2026Common StockSale21,926US$18.181,549,288Indirect
May 6, 2026Common StockSale43,621US$18.184,883,494Indirect
May 6, 2026Common StockSale428US$18.187,962Indirect
May 6, 2026Common StockSale17,244US$18.181,136,810Indirect

Source

View original at SEC

Related